News at a glance.

Press releases

All resultsAd hoc announcement pursuant to Art. 53 LRPress release
  • Press release, Monday, 5 June 2023

    Galenica continues to drive forward integrated and networked healthcare in Switzerland by acquiring a 16% stake in AD Swiss Ltd., the e-health provider for FMH, Ärztekasse and HIN. With “BENECURA public”, AD Swiss is able to offer digitally supported treatment programmes for people with chronic illnesses. Through this acquisition, Galenica is thus expanding its product range and services for those with chronic illnesses, and strengthening its network to other stakeholders in the healthcare sector.

    In Switzerland, around 2.7 million people are living with chronic conditions such as diabetes, and cardiovascular and respiratory diseases. In order to improve the medical care that chronically ill patients receive, six established organisations, all ideally connected within the Swiss healthcare system, have joined forces to form a network: Galenica, Ärztekasse, FMH, HIN, SWICA and Swiss Medical Network. The mutual aim of the network partners is to provide optimal care for chronically ill patients through a hybrid range of treatment options. “BENECURA public” and its app gives patients and service providers access to first-rate support during treatment. The app provides users with a wide range of digital services, such as the digital “SymptomCheck” tool, which was developed by doctors to offer individual treatment recommendations, “PreventionCheck” for preventive check-ups, “Ready for doctor” for independent preparation before doctor's visits, and a digital patient file, the "Health Dossier", that can be shared directly with the attending physician on request. In the future, the Galenica Group pharmacy formats will also be integrated into customer journeys, for example for specific consultations and medication purchases on-site, online or with an e-prescription.

    In this way, Galenica and its network partners are contributing to improving patients' quality of life, making them active participants in their own care process and improving the options available to service providers.

  • Ad hoc announcement pursuant to Art. 53 LR, Thursday, 11 May 2023

    Competition authorities in Switzerland and Austria have approved the planned joint venture between Galenica Ltd. and Shop Apotheke Europe N.V. This clears the way for the formation of Switzerland’s leading online pharmacy. The transaction establishing the joint venture will be completed on 16 May 2023.
  • Press release, Wednesday, 3 May 2023

    The shareholders elect Markus R. Neuhaus as the new Chair of the Board of Directors and approve all proposals

    The sixth Annual General Meeting of Galenica Ltd. was held on 3 May 2023 at the Kursaal in Bern. The shareholders approved all the proposals of the Board of Directors. They also approved the dividend proposal of CHF 2.20 per share, +5% on the previous year. The Annual General Meeting also elected Dr Markus R. Neuhaus as the new Chair of the Board of Directors and Prof. Dr med. Solange Peters and Jörg Zulauf as new members of the Board of Directors.


  • News, Tuesday, 8 November 2022

    In 2023, Galenica will grant all its employees a fixed cost-of-living adjustment. It is investing over CHF 14 million, thus increasing the payroll for its employees by a total of 3.1 per cent. Additional measures are being implemented for pharmacy staff to increase its attractiveness as an employer.

    All employees of the Galenica Group with a monthly salary of up to CHF 5,000 will receive a monthly salary increase of CHF 150. Employees with a monthly salary of over CHF 5,000 will receive CHF 100 per month (based on a 100% workload). By providing fixed and graduated cost-of-living adjustments, Galenica is sending a clear signal to its employees who are particularly affected by high inflation.

    In addition, Galenica is reaffirming its intention to address the shortage of skilled workers in the healthcare industry with additional measures for pharmacy staff.

    In pharmacies, entry-level salaries will be increased to CHF 4,100 to 4,500, depending on the region and canton. The recommendations of the cantonal pharmacists' associations will be used as a basis.
    The benchmark salaries for employees with work experience will be increased on the basis of the new entry-level salaries.

    Assuming a specific role by pharmacy specialists and thus taking on more responsibility – such as training apprentices – will in future be rewarded with position-related bonuses.

    The attractiveness as an employer is further increased with flat-rate mobility allowances, allowances for acting as a stand-in and team bonuses.

    Galenica is taking a further step towards covering the need for specialist staff in the future by providing a fixed cost-of-living adjustment for all employees as well as additional attractive measures for the pharmacy staff.

  • News, Wednesday, 21 September 2022

    Omni-channel – i.e. the link between online and offline – is a key element of the Galenica strategy. Contrary to earlier expectations, the Careproduct product range cannot be optimally integrated at Galenica. For this reason, Galenica is selling its subsidiary Careproduct to SAB Management Holding Ltd. and its owner Bruno Sauter, effective 20 September 2022.
  • News, Thursday, 8 September 2022

    After around 40 months of construction, Galexis opens the modernised distribution centre in Lausanne-Ecublens.

Subscribe to news

Media conferences and events


«Our communication focuses on the added value that we offer in the Galenica network for our customers and the Swiss healthcare system.»

Christina Hertig, Head of Corporate Communications

Media inquiries

Galenica Ltd.
Untermattweg 8
3027 Bern

Tel. +41 58 852 85 17